Ada Srl

A.D.A.(Advanced Drug Administration) is revolutionizing the treatment of interstitial lung diseases with nanotechnology-based inhalation therapies. Our mission is to improve outcomes and quality of life for patients with chronic and rare lung diseases, by transforming how respiratory therapies are designed and delivered By delivering drugs directly to the lungs, our approach enables localized treatment at the site of pathology, improving efficacy while reducing systemic side effects compared to conventional systemic therapies. A.D.A. leverages a “Drug AND Delivery” strategy, where the nanoparticle acts both as drug and carrier, enables more drug to reach the target site, eliminates the need for stabilizing excipients (avoiding excipient-related toxicity), and supports combination therapies, outperforming classic inhalation systems with traditional drug delivery.